Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Over 18
Pharmaceutical / Industry
PX-171-007
NCT00531284
2.
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
Pharmaceutical / Industry
PX-171-003
NCT00511238
3.
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
Over 18
Pharmaceutical / Industry
PX-171-002
NCT00150462
4.
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
PX-171-006
NCT00603447
5.
Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
PX-171-005
NCT00721734
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute